Document is current
Any future updates will be listed below
-
Authors
Goetz, Michael
Andrews-Higgins, Shaquita
Davis, Olivia A.
Back-Haddix, Sandra
Fanucchi, Laura
Lofwall, Michelle R.
Walsh, Sharon L.
Knudsen, Hannah K. https://orcid.org/0000-0002-0137-9337
-
Funding
Funding for this research was provided by:
National Institutes of Health (NIH) and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
- License Information
-
More Information
Article History
Received: 30 January 2026
Accepted: 22 June 2026
First Online: 27 June 2026
Declarations
:
: The study protocol was approved by Advarra Inc. (Protocol #Pro00038088), the single Institutional Review Board for the HEALing Communities Study, and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. All participants provided informed consent prior to participation. Participation was voluntary, and confidentiality protections were maintained throughout data collection and analysis.
: Not applicable.
: Michael Goetz, Hannah K. Knudsen, Shaquita Andrews-Higgins, Olivia Davis, Sandra Back-Haddix, and Laura Fanucchi declare that they have no competing interests. Michelle R. Lofwall has served as a research consultant for Braeburn Pharmaceuticals, Berkshire Biomedical, and Journey Colab, and has received a speaker honorarium for an invited research talk from Camurus. Sharon L. Walsh has served as a scientific advisor to Cerevel Therapeutics, AstraZeneca, Kinoxis, Reacx, Titan, Indivior, and Braeburn Pharmaceuticals.
